New Mexico protects clinical judgment.Its testing rule should do the same.
The Medical Board says pain treatment is legitimate, physical dependence is not addiction, and prescribing should be judged by the patient’s care rather than quantity or chronicity. Yet the same rule requires urine drug testing at initiation and at least every six months for every chronic pain patient receiving opioids. New Mexico can resolve that contradiction without weakening safety.
The state’s principle is individualized. Its test schedule is not.
16.10.14.9 NMAC requires urine drug testing when opioid therapy begins and at least every six months thereafter. That fixed schedule applies without a patient specific finding of risk, even though the rule elsewhere requires individualized treatment and equal attention to overprescribing and underprescribing.
Name the instrument before judging the effect.
A Medical Board rule, the Pain Relief Act, a prescription monitoring report, a payer requirement, and a clinic policy are not interchangeable. Each has a different owner, purpose, and route for correction.
16.10.14 NMAC
The Medical Board governs its licensees through standards for pain treatment, monitoring, documentation, testing, and discipline.
Pain Relief Act
Sections 24 2D 1 through 24 2D 6 supply part of the rule’s statutory authority and recognize pain management as a matter of public policy.
Medicaid, plans, and clinics
Payment criteria and institutional procedures may influence care, but they do not silently become the Medical Board’s standard.
The current rule contains three facts that belong together.
Treatment must fit the patient
The plan must be tailored to the patient’s needs, including age, gender, culture, ethnicity, function, and accepted measures of benefit.
Testing is automatic
Every chronic pain patient receiving opioids is subject to testing when therapy begins and at least every six months, regardless of a documented risk finding.
Underprescribing matters
The Board states that it reviews overprescribing and underprescribing under the same standard of patient protection and judges care by treatment and documentation, not quantity or chronicity.
Testing can inform care without controlling it.
Answer a clinical question
A properly selected and interpreted test may help identify an unexpected substance, absence of a prescribed medicine, interaction risk, or need for a more careful conversation.
Prove motive or diagnosis
A result does not by itself establish diversion, misuse, addiction, deception, impairment, or the correct treatment response.
Patient specific judgment
A practitioner may order testing when the patient’s history, condition, treatment, or observed risk makes it clinically useful.
Consent and continuity
A patient should receive an explanation of purpose and consequences, an opportunity to provide context, confirmation when appropriate, and a safe response to any concern.
Replace calendar testing with clinical indication.
- Amend 16.10.14.9 B 7 so testing is ordered when clinically indicated by a documented patient specific reason.
- Require informed discussion of the test’s purpose, limits, likely cost, medications or substances assessed, and possible treatment consequences.
- Require confirmation of an unexpected screening result before a nonemergency adverse decision when confirmation is clinically appropriate.
- Prohibit diagnosis, dismissal, forced tapering, or treatment interruption based solely on a single result, refusal, dosage threshold, or calendar interval.
- Require a written patient specific reason, prompt clinical review, and a safe transition when established treatment will change or end.
- Publish aggregate data on testing, confirmation, adverse decisions, reversals, costs, treatment interruption, and access.
Give the Medical Board text it can adopt.
When prescribing opioids for chronic pain, a practitioner may use toxicology testing when the practitioner documents a patient specific clinical reason and explains the purpose, material limitations, foreseeable cost, and possible treatment consequences to the patient.
An unexpected screening result shall be interpreted in clinical context and confirmed when appropriate before a nonemergency adverse decision. No patient shall be diagnosed, dismissed, required to taper, or denied established treatment solely because of a single result, refusal to test, dosage threshold, or elapsed time.
Turn a fixed mandate into accountable medicine.
Publish the baseline
Measure testing frequency, methods, cost, confirmation, clinical response, treatment interruption, and access across New Mexico.
Hear the affected record
Take testimony from patients, tribal communities, rural communities, clinicians, laboratories, pharmacists, disability advocates, payers, and recovery specialists.
Amend the rule
Replace the automatic schedule with documented clinical indication, meaningful discussion, reliable interpretation, and proportionate response.
Align every policy
Require Medicaid, health systems, clinics, laboratories, and plans to identify whether a testing requirement comes from law, coverage, contract, or local procedure.
Audit the outcome
Track testing, disputed results, confirmation, dismissal, tapering, review, reversal, emergency care, overdose, suicide risk, and regional access.
Make monitoring answerable to evidence.
Send each correction to its owner.
| Authority | Instrument | Proper request |
|---|---|---|
| New Mexico Medical Board | 16.10.14.9 B 7 NMAC | Replace automatic testing with clinically indicated, consent based monitoring and continuity protections. |
| New Mexico Legislature | Pain Relief Act | Strengthen individualized care, informed consent, and protection against nonclinical interruption. |
| Board of Pharmacy | PMP and pharmacy rules | Keep prescription history available while separating database indicators from clinical conclusions. |
| Health Care Authority | Medicaid coverage | Identify coverage requirements clearly and provide timely patient specific review. |
| Health systems, clinics, and laboratories | Operating policy | Explain test purpose, methods, cost, interpretation, and the route for review. |
New Mexico already wrote the foundation.
Keep the full treatment spectrum
The rule recognizes controlled substances as legitimate treatment and does not exclude patients who have addiction, physical dependence, or tolerance and also have legitimate pain.
Keep dependence distinct
The rule states that physical dependence and tolerance are normal physiological consequences of extended opioid therapy and do not by themselves constitute addiction.
Keep equal patient protection
The Board’s stated standard examines both overprescribing and underprescribing and focuses on treatment, documentation, function, and continuity rather than quantity or chronicity.
Open the controlling documents.
Precision protects the reform.
What the record supports
- The Medical Board rule requires urine testing at initiation and at least every six months during chronic opioid therapy.
- The same rule requires an individualized treatment plan and attention to function.
- Physical dependence and tolerance do not by themselves constitute addiction.
- The Board says it evaluates both overprescribing and underprescribing using the same patient protection standard.
What the record does not establish
- A test result alone proves diversion, misuse, addiction, or deception.
- New Mexico prohibits treatment above a fixed dosage.
- Every payer or clinic restriction is a Medical Board requirement.
- Individualized testing means abandoning monitoring or professional responsibility.
This Atlas is public policy education and source mapping, not legal advice or individual medical advice. Patients should not abruptly change medication or treatment based on this page.
Keep the protection standard. Make every test serve the patient.
New Mexico can preserve monitoring and professional responsibility while replacing automatic suspicion with clinical purpose, informed consent, reliable interpretation, and safe continuity.